Omnicell, Inc.
OMCLHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframeOmnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. The $1.54B market capitalization puts OMCL squarely in small-cap range for its industry. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process.
Market Cap
$1.54B
Beta
0.97
P/E (TTM)
40.33
P/E (Fwd)
16.21
EPS (TTM)
$0.84
EPS (Fwd)
$2.09
ROE
3.1%
ROA
1.5%
Cash
$292.2M
Total Debt
$200.0M
Free CF
$134.2M
52W Change
7.9%
Annual Financials
Cash vs Debt
Where OMCL stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, OMCL finished 12.24% below its 150-day moving average ($39.55) and 14.74% below its 200-day moving average ($40.71). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OMCL overbought or oversold?
At the September 3, 2026 close, OMCL's RSI(14) was 33.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $292.2M in cash and $200.0M in debt, OMCL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $134.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 3.1%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.5% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $1.13B (2021) to $1.18B (2025).
Investors considering Omnicell, Inc. should weigh the typical risks associated with OMCL's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing OMCL.